Evidence map›Paper›PMID 40563063›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Evaluating boron neutron capture therapy as a potential treatment for unresectable gastrointestinal stromal tumors.

Seita Hagihara, Jun Arima, Yasuhiko Ueda, Yosuke Inomata, Takafumi Shima, Minoru Suzuki, Sang-Woong Lee, Kohei Taniguchi

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Seita HagiharaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Jun ArimaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan. jun.arima@ompu.ac.jp.ORCID 0000-0002-4917-6256
Yasuhiko UedaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Yosuke InomataDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Takafumi ShimaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Minoru SuzukiDepartment of Particle Radiation Oncology, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro- Nishi, Kumatori-Cho, Sennan-Gun, Osaka, 590-0494, Japan.
Sang-Woong LeeDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Kohei TaniguchiCenter for Medical Research and Development, Division of Translational Research, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.

Funding

Japan Agency for Medical Research and Development JP25ama121052Japan Agency for Medical Research and Development JP25ama121054Japan Society for the Promotion of Science 21H02992
6 · The paper itself

Abstract

backgroundBoron neutron capture therapy selectively delivers the boron isotope

methodsThe GIST-T1 cell line and its imatinib-resistant variant (GIST-T1/IM-R) were utilized to assess boronophenylalanine uptake and evaluate boron neutron capture therapy efficacy in both in vitro and in vivo models.

resultsBoronophenylalanine was substantially incorporated into GIST-T1 and GIST-T1/IM-R cells. Boron neutron capture therapy significantly reduced survival fractions in both cell lines compared to neutron irradiation alone. In the GIST-T1 mouse model, high boronophenylalanine uptake was observed 3 h post-administration, resulting in significant tumor growth suppression following boron neutron capture therapy. Elevated expression of cleaved PARP, Caspase-3, Caspase-8, and γH2AX significantly increased in GIST-T1 tumors post-boron neutron capture therapy.

conclusionsThe results indicate that boron neutron capture therapy suppresses tumor growth by inducing extrinsic apoptosis through severe DNA damage. This study suggests that boron neutron capture therapy is a promising alternative treatment for gastrointestinal stromal tumors, particularly for cases exhibiting resistance to conventional therapies.

Indexed as

Boron Neutron Capture TherapyGastrointestinal NeoplasmsGastrointestinal Stromal TumorsAnimalsApoptosisBoron CompoundsCell Line, TumorDrug Resistance, NeoplasmFemaleHumansMiceMice, NudePhenylalanineXenograft Model Antitumor AssaysBoron CompoundsPhenylalanineBNCTBPAGISTImatinibLAT-1

Identifiers

PMID40563063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.